Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
lncRNA MIR22HG Derived miR-22-5p Enhanced Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Via Inhibiting HDAC2 Activity
39 Pages Posted: 10 May 2019
More...Abstract
Background: With the development of radiotherapy technology, Radiotherapy has been used increasingly to treat primary hepatocellular carcinoma (HCC). But due to the radioresistance and the intolerance of the adjacent organs, the effect of radiotherapy is not satisfactory. Therefore, it is necessary to study the radiosensitization of HCC.
Method: Microarray was used to analyze the significant gene associated with radiosensitivity. Application of HCC cells HepG2 and MHCC97H in vitro. Real-time PCR performed to determine MIR22HG (microRNA22 host gene) and miR-22-5p expression, western blot performed to determine histone expression. HDAC whole cell assay was sed to determine the activity of HDAC2. Then, MTT, colony formation, EDU, wound healing assays were to examine the function of MIR22HG and miR-22-5p on cellular radiosentivity. ChIP-PCR was used to confirm that HDAC2 affects the acetylation level of the MIR22HG promoter region. Finally, animal experiments were performed to demonstrate the effect MIR22HG on the radiosensitivity of hepatoma in vivo.
Results: Irradiation can upregulate MIR22HG expression and downregulate HDAC2 expression; Inhibition of HDAC2 expression promotes histone acetylation in the MIR22HG promoter region and up-regulates MIR22HG expression; MIR22HG can increase radiosensitivity via miR-22-5p in HCC.
Conclusion: Inhibition of HDAC2 expression promotes histone acetylation in the MIR22HG promoter region, thereby upregulating the expression of MIR22HG and promoting the production of miR-22-5p, ultimately increasing the sensitivity of liver cancer radiotherapy.
Funding: This work was supported by the National Natural Science Foundation of China (81872473), Key R & D projects of Hunan science and technology planning project (2017SK2052).
Declaration of Interest: The authors declare no conflicts of interest.
Ethical Approval: All experiments were approved by the Animal Center of China South University and performed following International Guidelines and Protocols.
Keywords: MIR22HG; miR-22-5p; radiosensitivity; hepatocellular carcinoma; HDAC2
Suggested Citation: Suggested Citation